Madrigal Pharmaceuticals (MDGL)
(Delayed Data from NSDQ)
$259.34 USD
+43.41 (20.10%)
Updated Oct 31, 2024 04:00 PM ET
After-Market: $259.00 -0.34 (-0.13%) 7:10 PM ET
3-Hold of 5 3
F Value F Growth C Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
MDGL 259.34 +43.41(20.10%)
Will MDGL be a Portfolio Killer in October?
Zacks Investment Research is releasing its prediction for MDGL based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for MDGL
Madrigal (MDGL) Reports Q3 Loss, Tops Revenue Estimates
Viking Therapeutics Stock: Buy or Sell Before Q3 Earnings?
MDGL: What are Zacks experts saying now?
Zacks Private Portfolio Services
Viking Stock Rises 29% in Three Months: Time to Buy, Hold or Sell?
SGMT Stock Up 12.6% on FDA Fast Track for Liver Disease Drug
Why Is Madrigal (MDGL) Up 1% Since Last Earnings Report?
Other News for MDGL
Madrigal Pharmaceuticals price target raised to $394 from $377 at Canaccord
Madrigal Pharmaceuticals price target raised by $17 at Canaccord, here's why
Madrigal Pharmaceuticals (MDGL) Shares Cross Above 200 DMA
Madrigal Pharmaceuticals, Inc. 2024 Q3 - Results - Earnings Call Presentation
12 Health Care Stocks Moving In Thursday's Pre-Market Session